海利尔药业集团股份有限公司 海利尔药业集团股份有限公司 2024 年年度股东大会会议议程 2024 年年度股东大会 一、会议召开的基本情况 会议材料 二、会议议程 二〇二五年五月二十二日 （一）会议类型和届次：2024 年年度股东大会 （二）会议召开时间、地点： 会议时间：2025 年 5 月 22 日 14:30-16:00 会议地点：青岛市城阳区国城路 216 号五楼会议室 （三）会议出席人员 1、股东、股东代表 2、公司董事、监事和高级管理人员 3、公司聘请的律师 4、其他人员 （一）全体与会股东或股东代表、列席会议的董事、监事、高级管理人员签到； （二）报告会议出席情况，宣布会议开始； （三）本次股东大会各项议案宣读并审议； （四）股东或股东代表发言及公司董事、监事、高级管理人员回答提问； （五）记名投票表决（由股东、监事及律师组成的表决统计小组进行统计）； （六）与会代表休息（工作人员统计现场投票结果），等待接收网络投票结果； （七）网络投票结果产生后，宣读投票结果和决议； （八）律师宣读本次股东大会法律意见书，董事在股东大会决议及会议记录上签字； （九）宣布会议结束。 海利尔药业集团股份有限公司 ...

海利尔药业集团股份有限公司 关于参加 2025 年青岛辖区上市公司投资者 网上集体接待日暨 2024 年度业绩说明会活动的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：603639 证券简称：海利尔 公告编号：2025-030 为进一步加强与投资者的互动交流，海利尔药业集团股份有限公司（以下简 称"公司"）将参加由青岛证监局指导，青岛市上市公司协会与深圳市全景网络 有限公司联合举办的"2025 年青岛辖区上市公司投资者网上集体接待日暨 2024 年度业绩说明会活动"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）；或关注微信公众号（名称：全景财经）；或下载全景路 演 APP,参与本次互动交流。活动时间为 2025 年 5 月 12 日（周一）15:00-17:00。 届时公司董事长葛家成先生，财务负责人刘玉龙先生，董事会秘书迟明明女士， 独立董事杨爱义先生将以在线交流形式就公司治理、发展战略、经营状况、融资 计划、股权激励和可持续 ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for future performance [5][7]. Core Insights - The company reported a decline in net profit for 2024 but showed improvement in Q1 2025, with a net profit of 1.05 billion yuan, a year-on-year increase of 15.64% and a quarter-on-quarter increase of 82.22% [1][2]. - The decrease in revenue for 2024 was primarily due to falling prices of certain pesticide products, which could not be offset by increased sales volume [2]. - The company is actively expanding its overseas market presence, having obtained over 2,100 product registrations in various countries [4]. Summary by Sections Financial Performance - In 2024, the company achieved revenue of 3.908 billion yuan, a year-on-year decrease of 11.16%, and a net profit of 181 million yuan, down 61.67% [1][6]. - For Q1 2025, revenue was 1.264 billion yuan, up 10.16% year-on-year and up 82.22% quarter-on-quarter, with a net profit of 105 million yuan [1][2]. Product and Market Strategy - The company is focusing on a strategy that integrates formulation, active ingredients, and intermediates, which helps mitigate the cyclical risks associated with active ingredient production [3]. - The company has a diverse product portfolio with 254 pesticide registration certificates, covering various categories such as insecticides, fungicides, and herbicides [4]. Profitability and Valuation - The report projects a decline in net profit for 2025 to 396 million yuan, down 28.6% from previous estimates, with further projections for 2026 and 2027 showing gradual recovery [5][6]. - The company's earnings per share (EPS) is expected to be 1.16 yuan in 2025, with a price-to-earnings (P/E) ratio of 11 [6][14].

Investment Rating - The report maintains an "Outperform" rating for the company [1] Core Views - The company reported better-than-expected performance driven by the peak season for formulations in Q1 2025, while continuing to advance the construction of the Hengning base to strengthen its integrated strategy of intermediates, active ingredients, and formulations [1][6] Financial Performance Summary - In 2024, the company achieved total revenue of 39.08 billion yuan, a year-on-year decrease of 11.2%, and a net profit attributable to the parent company of 1.81 billion yuan, down 61.7% year-on-year [5][6] - For Q1 2025, the company reported revenue of 12.64 billion yuan, a year-on-year increase of 10.2%, and a net profit of 1.05 billion yuan, up 16% year-on-year [6] - The company plans to distribute a cash dividend of 5 yuan per 10 shares, representing 93.7% of the net profit attributable to the parent company [6] Revenue and Profit Forecast - Projected total revenue for 2025 is 44.52 billion yuan, with a year-on-year growth rate of 13.9% [5] - The forecasted net profit for 2025 is 3.65 billion yuan, reflecting a significant increase of 101.3% compared to 2024 [5][6] - The company expects to gradually reduce losses from the Hengning base in 2025, with new investments supporting future growth [6] Market and Product Insights - The company's pesticide business saw a sales volume of 56,600 tons in 2024, with a revenue of 38.08 billion yuan, despite a year-on-year price decline of 14% [6] - In Q1 2025, the pesticide business achieved a sales volume of 17,200 tons, with revenue of 12.31 billion yuan, indicating a recovery in demand [6] - The report highlights that the formulation business is expected to contribute nearly half of the company's revenue during the peak sales season in H1 2025 [6]

Group 1 - The core viewpoint of the article highlights the strategic breakthroughs and innovations of Shandong Keda Group in the oilfield market, particularly in Southeast Asia, through the development of new high-temperature and salt-resistant polymers and modified polyacrylamide products [1] - Shandong Keda Group has maintained its competitive edge in traditional oilfield markets while successfully expanding into new markets, laying a solid foundation for its Asia-Pacific and global layout [1] - The company emphasizes the importance of continuous R&D innovation and optimizing product structure to create a series of high-quality products with core competitiveness [1] Group 2 - Shandong Keda Group has been recognized as a top 500 Chinese enterprise for 18 consecutive years and is the only private enterprise in Shandong with a special-grade qualification for highway engineering construction [3] - The company has leveraged its multi-sector collaboration advantages in various projects, such as highways and bridges, to shorten project preparation cycles and improve profit margins [3] - Keda Group has implemented a comprehensive incentive mechanism for talent development in emerging business areas, focusing on performance rewards, growth empowerment, and shared benefits [3] Group 3 - Zhongfu Information Co., Ltd. is noted as one of the earliest private enterprises in China engaged in the research and development of confidentiality and security products, and it was the first in the sector to be listed on the A-share market [3] - The company has established a nationwide market and technical service network, focusing on confidentiality and data security, and aims to enhance its product competitiveness in response to evolving user demands [4][5] - Hailier Pharmaceutical Group, founded in 1999, specializes in agricultural pest control and has become a global leader in the supply of various pesticide products, with operations in over 100 countries [5] Group 4 - Hailier Pharmaceutical Group invests over 4.5% of its annual revenue in R&D, focusing on green raw materials and environmentally friendly formulations, and has developed new pesticides that increase crop yields by 30% [5] - The company is also engaged in the development of nano-pesticides and biological pesticides that meet drone application standards [5] Group 5 - Recent policies in Shandong, such as the "38 measures for the private economy" and "comprehensive economic stabilization policies," aim to promote economic development by simplifying approval processes and optimizing the business environment for private enterprises [6]

Core Viewpoint - The company reported a decline in revenue and net profit for the year 2024, primarily due to falling prices of pesticide products, despite an increase in production and sales volume [18]. Group 1: Company Overview - The company, Haier Pharmaceutical Group Co., Ltd., is engaged in the research, production, and sales of pesticide formulations, intermediates, and raw materials, with a focus on insecticides and fungicides [4][15]. - The pesticide industry is characterized by relatively inelastic demand, playing a crucial role in agricultural production and food security [2][3]. Group 2: Financial Performance - The company achieved operating revenue of CNY 3.91 billion in 2024, a decrease of 11.16% from CNY 4.40 billion in 2023 [18]. - The net profit attributable to shareholders was CNY 181.37 million, down 61.67% from CNY 473.20 million in the previous year [18]. - The net cash flow from operating activities was CNY 285.55 million, a significant decrease of 70.11% compared to CNY 955.35 million in 2023 [18]. Group 3: Market Dynamics - The global demand for pesticides is expected to grow due to increasing food security needs and agricultural efficiency [2]. - China's pesticide production capacity is shifting towards countries like China and India, driven by the expiration of patents and restructuring by multinational agrochemical giants [2][3]. Group 4: Product Development - The company has been diversifying its pesticide offerings, with several new products entering trial production in recent years, including various insecticides and fungicides [4][5]. - The company is focusing on high-efficiency, low-toxicity pesticides to meet the growing market demand [2][4]. Group 5: Industry Trends - The pesticide industry is experiencing a shift towards biopesticides and environmentally friendly products, with increasing market share for biological and chemical pesticides [7]. - The market for generic pesticides is expected to expand as patents expire, providing opportunities for companies with strong R&D capabilities [2][3].

证券代码：603639 证券简称：海利尔 公告编号：2025-020 海利尔药业集团股份有限公司 关于公司向金融机构申请2025年度综合授信额度及提供相 应担保额度预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次授信金额：海利尔药业集团股份有限公司（以下简称"公司"）及 子公司预计2025年度向银行等金融机构申请不超过40亿元的综合授信敞口额度。 被担保人名称：公司、青岛奥迪斯生物科技有限公司（以下简称"奥迪 斯生物"）、山东海利尔化工有限公司（以下简称"山东海利尔"）、青岛凯源 祥化工有限公司（以下简称"凯源祥化工"）、青岛恒宁生物科技有限公司（以 下简称"恒宁生物"）、上海海加生物科技有限公司（以下简称"上海海加"）、 青岛海利尔农业服务有限公司（以下简称"海利尔农业服务"）。被担保人为公 司及公司合并报表范围内子公司。 本次担保金额及已实际为其提供的担保金额：预计 2025 年度公司拟为子 公司提供担保、子公司为公司提供担保的额度合计不超过人民币 40 亿元。截至 本公告日，公司为子公司已 ...

海利尔药业集团股份有限公司 证券代码：603639 证券简称：海利尔 公告编号：2025-016 2024 年年度主要经营数据公告 | 主要产品 | 2024 年度 | | 2023 年度 | | 变动比 | | --- | --- | --- | --- | --- | --- | | | 平均进价（万元/吨） | | 平均进价（万元/吨） | | 率（%） | | 丙烯腈 | | 0.82 | | 0.80 | 2.13 | | 二甲基甲酰胺(DMF) | | 0.39 | | 0.46 | -14.52 | | 甲苯 | 0.62 | 0.65 | -4.54 | | --- | --- | --- | --- | | 一甲胺精品 | 0.40 | 0.53 | -25.84 | | 液氯 | 0.028 | 0.026 | 7.95 | 四、其他对公司生产经营具有重大影响的事项 以上生产经营数据，来自公司内部统计，未经审计，仅为投资者及时了解公 司生产经营概况之用，未对公司未来经营情况作出任何明示或默示的预测或保证。 公司董事会提醒投资者审慎使用上述数据。 本公司董事会及全体董事保证本公告内容不存在任 ...

公司代码：603639 公司简称：海利尔 海利尔药业集团股份有限公司 2024年度内部控制评价报告 海利尔药业集团股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责组织 领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告内容不存 在任何虚假记载、误导性陈述或重大遗漏，并对报告内容的真实性、准确性和完整性承担个别及连带法 律责任。 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能 ...

三、审计委员会对会计师事务所监督情况 根据《海利尔药业集团股份有限公司审计委员会工作细则》等有关规定，审计 委员会对会计师事务所履行监督职责的情况如下： 海利尔药业集团股份有限公司董事会审计委员会 对会计师事务所履行监督职责情况报告 根据《中华人民共和国公司法》《中华人民共和国证券法》《上市公司治理准 则》《国有企业、上市公司选聘会计师事务所管理办法》等规定和要求，董事会审 计委员会本着勤勉尽责的原则，恪尽职守，认真履职。现将董事会审计委员会对会 计师事务所履行监督职责的情况汇报如下： 一、会计师事务所的基本信息 中兴华会计师事务所（特殊普通合伙）（以下简称"中兴华"）成立于 1993 年，注册地址为北京市丰台区丽泽路 20 号院 1 号楼南楼 20 层。截至 2024 年 12 月 31 日止，中兴华拥有合伙人 199 人、注册会计师 1052 人、签署过证券服务业务审 计报告的注册会计师 522 人。 二、聘任会计师事务所的审议程序 经公司第五届董事会审计委员会第一次会议、第五届董事会第四次会议及 2023 年年度股东大会审议，同意续聘中兴华担任公司 2024 年度审计机构。公司董事会 审计委员会提前审议 ...